|
|
Post by mango on Jan 4, 2019 15:13:20 GMT -5
• Sumatriptan (Think Mike said "a triptan", just putting that up since it has been on their Bucket 2 slide before)
• 5-HT3 Inhibitor (Think Mike said "a 5-HT3 inhibitor")
• Tobramycin
• Undisclosed
|
|
|
|
Post by #NoMoreNeedles on Jan 4, 2019 15:22:33 GMT -5
5HT3 inhibitor for chemotherapy-induced nausea and vomiting. Isn't that Dronabinol through RLS?
|
|
|
|
Post by #NoMoreNeedles on Jan 4, 2019 15:23:43 GMT -5
|
|
|
|
Post by peppy on Jan 4, 2019 15:25:22 GMT -5
• Sumatriptan (Think Mike said "a triptan", just putting that up since it has been on their Bucket 2 slide before) • 5-HT3 Inhibitor (Think Mike said "a 5-HT3 inhibitor") • Tobramycin • Undisclosed Tadalafil. pi.lilly.com/us/adcirca-pi.pdfwww.unither.com/products.htmlAdcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).  |
|
|
|
Post by mango on Jan 4, 2019 15:44:59 GMT -5
5HT3 inhibitor for chemotherapy-induced nausea and vomiting. Isn't that Dronabinol through RLS? Dronabinol is synthetic THC. |
|
|
|
Post by mango on Jan 4, 2019 15:53:20 GMT -5
• Sumatriptan (Think Mike said "a triptan", just putting that up since it has been on their Bucket 2 slide before) • 5-HT3 Inhibitor (Think Mike said "a 5-HT3 inhibitor") • Tobramycin • Undisclosed Tadalafil. pi.lilly.com/us/adcirca-pi.pdfwww.unither.com/products.htmlAdcirca is a phosphodiesterase 5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH)(WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). You think that is the undisclosed? Wouldn't this be the inhaled DPI PDE5 that's listed on UT's pipeline? |
|
|
|
Post by mango on Jan 4, 2019 15:55:30 GMT -5
Mike said the Undisclosed molecule was consumer driven and is on hush due to competitive reasons.
|
|
|
|
Post by mango on Jan 4, 2019 16:00:10 GMT -5
• Number one, a triptan for acute migraine, number two, a 5HT3 inhibitor for chemotherapy-induced nausea and vomiting. Number three, inhaled tobramycin for cystic fibrosis, and the fourth one is an undisclosed compound targeting a large consumer driven market that we are keeping confidential for competitive reasons.
• These four molecules are within our current capital allocation for 2019. Our clinical development team is working hard to bring these molecules forward and the opportunity presents itself through partnerships to bring more things forward such as epinephrine that we believe serve an unmet need, but don't meet our screening criteria as I’ve previously talked about. Our website will be updated shortly to reflect these new additions.
|
|
|
|
Post by peppy on Jan 4, 2019 16:02:04 GMT -5
|
|
|
|
Post by mango on Jan 4, 2019 16:13:24 GMT -5
Hmmm.... So it's something that's OTC you think? That would be interesting. Wonder what it is... |
|
|
|
Post by goyocafe on Jan 4, 2019 16:14:48 GMT -5
Mike said the Undisclosed molecule was consumer driven and is on hush due to competitive reasons. And all the marketing minds in all of the other big pharmaceutical cos in the world/US haven’t thought of this consumer driven molecule? The statement leaves me feeling like I just had another carrot dangled in front of me, like RLS. So let’s revisit this one in a couple of years. |
|
|
|
Post by mannmade on Jan 4, 2019 16:18:01 GMT -5
5HT3 inhibitor for chemotherapy-induced nausea and vomiting. Isn't that Dronabinol through RLS? Isn’t the RLS deal for a anti nausea treatment for cancer patients? If so do they compete? |
|
|
|
Post by goyocafe on Jan 4, 2019 16:31:44 GMT -5
5HT3 inhibitor for chemotherapy-induced nausea and vomiting. Isn't that Dronabinol through RLS? Isn’t the RLS deal for a anti nausea treatment for cancer patients? If so do they compete? If it’s an existing drug formulated for inhalation, perhaps the time to market is shortened, and possibly more profitable since they would own it outright. |
|
|
|
Post by Clement on Jan 4, 2019 16:43:33 GMT -5
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. www.ncbi.nlm.nih.gov/pubmed/16163194maybe? |
|
|
|
Post by mango on Jan 4, 2019 16:44:27 GMT -5
This sounds interesting ya'll
"Take the migraine for example. I look at Novartis, Lilly and Teva all have built large chronic prevention sales forces for migraines. No one is now treating the acute episode, that’s still occurring after time. And I believe that there will be an opportunity in the migraines space where a better triptan deliver faster onset because that’s what people were going to expect that day. They’ve diminished the number of frequencies of chronic migraines, but now they can address the acute ones which are still pretty severe, a lot less frequent but if we get a better onset in that particular setting that’s an area we’re focused on sort like the triptan."
"On the chemotherapy-induced nausea and vomiting one, we look at this as again we saw some pulmonary data out there in the marketplace that would highlight an inhaled version of these products. We get a fast onset. We think it needs a unique profile and there’s a lot of companies building Oncology sales forces who will just need another product in the bag. A single product sales force as we look out, we’ve made it through the worst but not an easy journey for the company and I think that’s something that we’re hearing more and more from Wall Street is they want people to have more shots on goal, and we have a pipeline fortunately moving forward now. That’s just a couple of examples of how we look at the pipeline."
|
|
